

Yorvipath (palopegteriparatide)
Effective 05/01/2025

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Medical Benefit Pharmacy Benefit	Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
Exceptions	N/A		

Overview

Yorvipath (palopegteriparatide) is a parathyroid hormone analog (PTH(1-34)) indicated for the treatment of hypoparathyroidism in adults.

Yorvipath has not been studied for acute post-surgical hypoparathyroidism. The titration scheme has only been evaluated in adults who first achieved an albumin-corrected serum calcium of at least 7.8 mg/dL using calcium and active vitamin D treatment.

Coverage Guidelines

Authorization may be granted for members new to the plan within the past 90 days who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

OR

Authorization may be granted for members when all of the following criteria are met:

1. Diagnosis of hypoparathyroidism for at least 6 months
2. Member has achieved an albumin-adjusted serum calcium level of at least 7.8 mg/dL with calcium and active vitamin D (calcitriol)
3. Requested medication is prescribed by or in consultation with an endocrinologist

Continuation of Therapy

Requests for continuation of therapy will be approved when the following criteria are met:

1. Member demonstrates a positive response to therapy as evidenced by maintenance of normalized calcium levels compared to baseline

Limitations

1. Initial requests will be approved for 6 months
2. Reauthorization requests will be approved for 12 months
3. Yorvipath will not be approved in the setting of acute post-surgical hypoparathyroidism
4. The following quantity limits apply:

Drug Name	Quantity Limit
Yorvipath pen	2 pens per 28 days

References

1. Babey M, Brandi ML, Shoback D. Conventional treatment of hypoparathyroidism. *Endocrinol Metab Clin N Am*. 2018;47(4):889-900.
2. Bollerslev J, Rejnmark L, Marcocci C, et al. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. *Eur J Endocrinol*. 2015;173(2):G1-G20.
3. Brandi ML, Bilezikian JP, Shoback D, et al. Management of hypoparathyroidism: Summary statement and guidelines. *J Clin Endocrinol Metab*, 2016;101(6):2273–2283.
4. Clarke BL, Khan AA, Rubin MR, et al. Efficacy and safety of TransCon PTH in adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway trial. *J Clin Endocrinol Metab*. 2024:dgae693. doi: 10.1210/clinem/dgae693. Online ahead of print.
5. Clarke BL, Brown EM, Collins MT, et al. Epidemiology and diagnosis of hypoparathyroidism. *J Clin Endocrinol Metab*. 2016;101(6):2284-2299. doi: 10.1210/jc.2015-3908. Epub March 4, 2016.
6. Gafni RI, Collins MT. Hypoparathyroidism. *N Engl J Med*. 2019;380:1738-1747.
7. Gut L, Bernet S, Huembelin M, et al. Sex-specific differences in outcomes following thyroidectomy: A population-based cohort study. *Eur Thyroid J*. 2020;10(6):476-485. doi: 10.1159/000510618. Epub September 30, 2020.
8. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. 2011;64(4):383-394. doi: 10.1016/j.jclinepi.2010.04.026. Epub December 31, 2010.
9. Khan AA, Bilezikian JP, Brandi ML, et al. Evaluation and management of hypoparathyroidism summary statement and guidelines from the Second International Workshop. *J Bone Miner Res*. 2022(a);37(12):2568-2585. doi: 10.1002/jbmr.4691. Epub November 14, 2022.
10. Khan AA, Guyatt G, Ali DS, et al. Management of hypoparathyroidism. *J Bone Miner Res*. 2022(b);37(12):2663-2677. doi: 10.1002/jbmr.4716. Epub October 31, 2022.
11. Khan AA, Koch CA, Van Uum S, et al. Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. *Eur J Endocrinol*. 2019;180:1-23.
12. Khan AA, Rubin MR, Schwarz P, et al. Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial. *J Bone Miner Res*. 2023;38(1):14-25. doi: 10.1002/jbmr.4726. Epub November 12, 2022.
13. Puliani G, Hasenmajer V, Simonelli I, et al. Safety and efficacy of PTH 1-34 and 1-84 therapy in chronic hypoparathyroidism: A meta-analysis of prospective trials. *J Bone Miner Res*. 2022;37(7):1233-1250. doi: 10.1002/jbmr.4566. Epub May 20, 2022.
14. Rejnmark L. Treatment of hypoparathyroidism by re-establishing the effects of parathyroid hormone. *Endocrinol Metab*. 2024;39:262-266. doi: 10.3803/EnM.2024.1916. Epub April 4, 2024.
15. Rejnmark L, Gosmanova EO, Khan AA, et al. Palopegteriparatide treatment improves renal function in adults with chronic hypoparathyroidism: 1-year results from the phase 3 PaTHway trial. *Adv Ther*. 2024;41:2500-2518. doi: 10.1007/s12325-024-02843-8. Epub April 30, 2024.
16. Tecilazich F, Formenti AM, Frara S, Giubbini R, Giustina A. Treatment of hypoparathyroidism. *Best Pract Res Clin Endocrinol Metab*. 2018;32(6):955-964. doi: 10.1016/j.beem.2018.12.002. Epub December 6, 2018.
17. Yao L, Li J, Li M, et al. Parathyroid hormone therapy for managing chronic hypoparathyroidism: A systematic review and meta-analysis. *J Bone Miner Res*. 2022;37(12):2654–2662. doi: 10.1002/jbmr.4676. Epub November 16, 2022.



18. Yorvipath (palopegteriparatide) [prescribing information]. Princeton, NJ: Ascendis Pharma; August 2024.

Review History

02/12/2025 – Reviewed and February P&T. Effective 05/01/2025.

